Literature DB >> 23617655

Unilateral versus bilateral endoscopic biliary stenting for malignant hilar biliary strictures.

Ichiro Yasuda1, Tsuyoshi Mukai, Hisataka Moriwaki.   

Abstract

The present review compared unilateral versus bilateral stenting in order to determine the optimal stenting strategy for malignant hilar biliary strictures based on the previous literature. The role of preoperative biliary drainage prior to liver resection for hilar cholangiocarcinoma remains under discussion. However, in Japan, endoscopic placement of single nasobiliary drainage in the future remnant hepatic lobe is currently considered the most suitable method. In most unresectable cases, unilateral stenting appears to be adequate for ameliorating jaundice. It is technically easier and less expensive than bilateral stenting, with reintervention for stent dysfunction also being considerably easier. However, contrast medium injection into undrained bile ducts is associated with uncontrolled cholangitis and poor prognosis. To prevent this complication, bilateral stenting may be preferred to unilateral stenting. Additionally, previous studies have demonstrated bilateral stenting to be associated with longer stent patency as compared to unilateral stenting. We consider that further large-scale studies are required to clarify whether unilateral or bilateral stenting is a better therapeutic technique for malignant hilar biliary stricture.
© 2013 The Authors. Digestive Endoscopy © 2013 Japan Gastroenterological Endoscopy Society.

Entities:  

Mesh:

Year:  2013        PMID: 23617655     DOI: 10.1111/den.12060

Source DB:  PubMed          Journal:  Dig Endosc        ISSN: 0915-5635            Impact factor:   7.559


  11 in total

1.  What is the current role of endoscopy in primary sclerosing cholangitis?

Authors:  Benjamin Tharian; Nayana Elizabeth George; Tony Chiew Keong Tham
Journal:  World J Gastrointest Endosc       Date:  2015-08-10

2.  Endoscopic "crossroads" in the management of malignant hilar strictures.

Authors:  Shajan Peter; Charles M Wilcox
Journal:  Indian J Gastroenterol       Date:  2013-10-26

Review 3.  Endoscopic palliation of malignant biliary strictures.

Authors:  Sanjay M Salgado; Monica Gaidhane; Michel Kahaleh
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

4.  Locoregional therapies in cholangiocarcinoma.

Authors:  Peter L Labib; Brian R Davidson; Ricky A Sharma; Stephen P Pereira
Journal:  Hepat Oncol       Date:  2017-11-17

Review 5.  Advances in endoscopic retrograde cholangiopancreatography for the treatment of cholangiocarcinoma.

Authors:  Dushant S Uppal; Andrew Y Wang
Journal:  World J Gastrointest Endosc       Date:  2015-06-25

Review 6.  Endoscopic and Photodynamic Therapy of Cholangiocarcinoma.

Authors:  Benjamin Meier; Karel Caca
Journal:  Visc Med       Date:  2016-11-30

7.  Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells.

Authors:  Tae Won Kwak; Hye Lim Lee; Yeon Hui Song; Chan Kim; Jungsoo Kim; Sol-Ji Seo; Young-Il Jeong; Dae Hwan Kang
Journal:  Int J Nanomedicine       Date:  2017-10-17

8.  Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma.

Authors:  Yongjiang Ba; Ping Yue; Joseph W Leung; Haiping Wang; Yanyan Lin; Bing Bai; Xiaoliang Zhu; Lei Zhang; Kexiang Zhu; Wenhui Wang; Wenbo Meng; Wence Zhou; Ying Liu; Xun Li
Journal:  Endosc Int Open       Date:  2020-01-22

9.  Predictive factors for the failure of endoscopic stent-in-stent self-expandable metallic stent placement to treat malignant hilar biliary obstruction.

Authors:  Mitsuru Sugimoto; Tadayuki Takagi; Rei Suzuki; Naoki Konno; Hiroyuki Asama; Ko Watanabe; Jun Nakamura; Hitomi Kikuchi; Yuichi Waragai; Mika Takasumi; Yuki Sato; Takuto Hikichi; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2017-09-14       Impact factor: 5.742

10.  Application of 3D visualization and 3D printing technology on ERCP for patients with hilar cholangiocarcinoma.

Authors:  Yan Yang; Zhongyin Zhou; Rong Liu; Lu Chen; Hongyu Xiang; Na Chen
Journal:  Exp Ther Med       Date:  2018-02-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.